List of Xtoro drug patents

Xtoro is owned by Merlion Pharms Gmbh.

Xtoro contains Finafloxacin.

Xtoro has a total of 4 drug patents out of which 0 drug patents have expired.

Xtoro was authorised for market use on 17 December, 2014.

Xtoro is available in suspension/drops;otic dosage forms.

Xtoro can be used as treatment of acute otitis externa.

The generics of Xtoro are possible to be released after 21 November, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9119859 MERLION PHARMS GMBH Methods for treating otic infections
Jul, 2030

(7 years from now)

US9993483 MERLION PHARMS GMBH Compositions and methods for treating ophthalmic, octic, or nasal infections
Jul, 2030

(7 years from now)

US8536167 MERLION PHARMS GMBH Methods for treating ophthalmic, otic, or nasal infections
Aug, 2031

(8 years from now)

US9504691 MERLION PHARMS GMBH Finafloxacin suspension compositions
Nov, 2033

(10 years from now)

Drugs and Companies using FINAFLOXACIN ingredient

Market Authorisation Date: 17 December, 2014

Treatment: Treatment of acute otitis externa


More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic